Shares of OptiNose Inc (NASDAQ:OPTN) reached a new 52-week low on Tuesday . The company traded as low as $7.33 and last traded at $7.60, with a volume of 5150 shares traded. The stock had previously closed at $7.60.
A number of analysts have weighed in on the company. Zacks Investment Research lowered OptiNose from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Cantor Fitzgerald set a $30.00 target price on OptiNose and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Piper Jaffray Companies set a $30.00 target price on OptiNose and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Finally, BMO Capital Markets reduced their target price on OptiNose from $30.00 to $28.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 15th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $28.75.
The company has a market cap of $324.46 million, a P/E ratio of -1.32 and a beta of -0.57. The company has a quick ratio of 10.13, a current ratio of 10.44 and a debt-to-equity ratio of 0.51.
Institutional investors have recently made changes to their positions in the company. Thompson Davis & CO. Inc. purchased a new position in shares of OptiNose during the second quarter valued at $105,000. Summit Trail Advisors LLC purchased a new position in shares of OptiNose during the second quarter valued at $109,000. MetLife Investment Advisors LLC purchased a new position in shares of OptiNose during the third quarter valued at $157,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of OptiNose during the third quarter valued at $230,000. Finally, Sio Capital Management LLC purchased a new position in shares of OptiNose during the third quarter valued at $336,000. Hedge funds and other institutional investors own 50.30% of the company’s stock.
WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2018/12/04/optinose-optn-hits-new-52-week-low-at-7-33.html.
About OptiNose (NASDAQ:OPTN)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Featured Article: Bear Market – How and Why They Occur
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.